FREQUENCY AND CLINICAL IMPLICATIONS OF SOX11 EXPRESSION IN BURKITT LYMPHOMA
(Abstract release date: 05/19/16)
EHA Library. Wästerlid T. 06/09/16; 132530; E981
Dr. Tove Wästerlid
Contributions
Contributions
Abstract
Abstract: E981
Type: Eposter Presentation
Background
The transcription factor SOX11 is normally expressed during embryogenesis in humans. Several studies have shown that SOX11 is aberrantly expressed in various types of haematopoetic and solid malignancies, and appears to affect clinicopathological characteristics. In mantle cell lymphoma, SOX11 serves as a diagnostic antigen and has been shown to be associated with superior outcome (Nordström et al. British Journal of Haematology 2014), although its role as a prognostic indicator remains controversial. In chronic lymphocytic leukemia, SOX11 was associated with inferior overall survival (Roisman et al. Tumor Biol 2015), whereas SOX11 expression correlated with superior outcome in epithelial ovarian cancer (Sernbo et al. BMC Cancer 2011). Various possible target genes and transcriptional programs have been identified, by which SOX11 may exert both repressive, and exaggerative, functions on proliferation (Kuo et al. Oncogene 2015, Vegliante et al. Blood 2013). In Burkitt lymphoma (BL), two small series have reported expression of SOX11 in 30-50 % of cases (Mozos et al. Haematologica 2009, Dictor et al. Haematologica 2009). As of yet, no study has been performed specifically to evaluate the implication of SOX11 expression in BL.
Aims
The aim of this study was to investigate the frequency of SOX11 positive BL cases in a larger joint cohort from Denmark and Sweden, and correlate its expression to clinical and pathological parameters.
Methods
45 BL cases were collected from Sweden and Denmark. Samples were analyzed for expression of SOX11 and other immunohistochemical markers. Clinical data were obtained from the Danish Lymphoma Database (LYFO) and the Swedish Lymphoma Registry. Additionally, 9 pediatric BL cases were analyzed for SOX11 expression, but with no clinical data available.
Results
In the adult study population, 14/45 (31 %) expressed nuclear staining of SOX11. The SOX11 positive subgroup had a higher median age (53 compared to 41), as well as a larger proportion with elevated LDH. Other prognostic factors were equally distributed between the groups. Although a similar proportion of patients received high-intensive chemotherapy in both subgroups, 3 (21 %) received no treatment in the SOX11 positive cohort. There was no significant difference in immunohistochemical characteristics between SOX11 positive and negative cases.Five-year overall survival (OS) in the SOX11 positive group was 57 %, compared to 77 % in the SOX11 negative cohort. When adjusting for treatment and and prognostic factors in multivariable analysis, no significant difference in outcome was seen between groups (hazard ratio: 1.5, 95 % confidence interval: 0.3-6.3, p=0.6). In the pediatric cohort, 5/9 (56 %) expressed SOX11.
Conclusion
SOX11 expression was found in a minority of BL cases, and was associated with higher age in the adult BL cohort. In contrast to SOX11 expression in other malignancies, SOX11 expression showed no significant impact on outcome, in our study, when adjusting for prognostic factors and treatment.
Session topic: E-poster
Keyword(s): Burkitt's lymphoma, Transcription factor
Type: Eposter Presentation
Background
The transcription factor SOX11 is normally expressed during embryogenesis in humans. Several studies have shown that SOX11 is aberrantly expressed in various types of haematopoetic and solid malignancies, and appears to affect clinicopathological characteristics. In mantle cell lymphoma, SOX11 serves as a diagnostic antigen and has been shown to be associated with superior outcome (Nordström et al. British Journal of Haematology 2014), although its role as a prognostic indicator remains controversial. In chronic lymphocytic leukemia, SOX11 was associated with inferior overall survival (Roisman et al. Tumor Biol 2015), whereas SOX11 expression correlated with superior outcome in epithelial ovarian cancer (Sernbo et al. BMC Cancer 2011). Various possible target genes and transcriptional programs have been identified, by which SOX11 may exert both repressive, and exaggerative, functions on proliferation (Kuo et al. Oncogene 2015, Vegliante et al. Blood 2013). In Burkitt lymphoma (BL), two small series have reported expression of SOX11 in 30-50 % of cases (Mozos et al. Haematologica 2009, Dictor et al. Haematologica 2009). As of yet, no study has been performed specifically to evaluate the implication of SOX11 expression in BL.
Aims
The aim of this study was to investigate the frequency of SOX11 positive BL cases in a larger joint cohort from Denmark and Sweden, and correlate its expression to clinical and pathological parameters.
Methods
45 BL cases were collected from Sweden and Denmark. Samples were analyzed for expression of SOX11 and other immunohistochemical markers. Clinical data were obtained from the Danish Lymphoma Database (LYFO) and the Swedish Lymphoma Registry. Additionally, 9 pediatric BL cases were analyzed for SOX11 expression, but with no clinical data available.
Results
In the adult study population, 14/45 (31 %) expressed nuclear staining of SOX11. The SOX11 positive subgroup had a higher median age (53 compared to 41), as well as a larger proportion with elevated LDH. Other prognostic factors were equally distributed between the groups. Although a similar proportion of patients received high-intensive chemotherapy in both subgroups, 3 (21 %) received no treatment in the SOX11 positive cohort. There was no significant difference in immunohistochemical characteristics between SOX11 positive and negative cases.Five-year overall survival (OS) in the SOX11 positive group was 57 %, compared to 77 % in the SOX11 negative cohort. When adjusting for treatment and and prognostic factors in multivariable analysis, no significant difference in outcome was seen between groups (hazard ratio: 1.5, 95 % confidence interval: 0.3-6.3, p=0.6). In the pediatric cohort, 5/9 (56 %) expressed SOX11.
Conclusion
SOX11 expression was found in a minority of BL cases, and was associated with higher age in the adult BL cohort. In contrast to SOX11 expression in other malignancies, SOX11 expression showed no significant impact on outcome, in our study, when adjusting for prognostic factors and treatment.
Session topic: E-poster
Keyword(s): Burkitt's lymphoma, Transcription factor
Abstract: E981
Type: Eposter Presentation
Background
The transcription factor SOX11 is normally expressed during embryogenesis in humans. Several studies have shown that SOX11 is aberrantly expressed in various types of haematopoetic and solid malignancies, and appears to affect clinicopathological characteristics. In mantle cell lymphoma, SOX11 serves as a diagnostic antigen and has been shown to be associated with superior outcome (Nordström et al. British Journal of Haematology 2014), although its role as a prognostic indicator remains controversial. In chronic lymphocytic leukemia, SOX11 was associated with inferior overall survival (Roisman et al. Tumor Biol 2015), whereas SOX11 expression correlated with superior outcome in epithelial ovarian cancer (Sernbo et al. BMC Cancer 2011). Various possible target genes and transcriptional programs have been identified, by which SOX11 may exert both repressive, and exaggerative, functions on proliferation (Kuo et al. Oncogene 2015, Vegliante et al. Blood 2013). In Burkitt lymphoma (BL), two small series have reported expression of SOX11 in 30-50 % of cases (Mozos et al. Haematologica 2009, Dictor et al. Haematologica 2009). As of yet, no study has been performed specifically to evaluate the implication of SOX11 expression in BL.
Aims
The aim of this study was to investigate the frequency of SOX11 positive BL cases in a larger joint cohort from Denmark and Sweden, and correlate its expression to clinical and pathological parameters.
Methods
45 BL cases were collected from Sweden and Denmark. Samples were analyzed for expression of SOX11 and other immunohistochemical markers. Clinical data were obtained from the Danish Lymphoma Database (LYFO) and the Swedish Lymphoma Registry. Additionally, 9 pediatric BL cases were analyzed for SOX11 expression, but with no clinical data available.
Results
In the adult study population, 14/45 (31 %) expressed nuclear staining of SOX11. The SOX11 positive subgroup had a higher median age (53 compared to 41), as well as a larger proportion with elevated LDH. Other prognostic factors were equally distributed between the groups. Although a similar proportion of patients received high-intensive chemotherapy in both subgroups, 3 (21 %) received no treatment in the SOX11 positive cohort. There was no significant difference in immunohistochemical characteristics between SOX11 positive and negative cases.Five-year overall survival (OS) in the SOX11 positive group was 57 %, compared to 77 % in the SOX11 negative cohort. When adjusting for treatment and and prognostic factors in multivariable analysis, no significant difference in outcome was seen between groups (hazard ratio: 1.5, 95 % confidence interval: 0.3-6.3, p=0.6). In the pediatric cohort, 5/9 (56 %) expressed SOX11.
Conclusion
SOX11 expression was found in a minority of BL cases, and was associated with higher age in the adult BL cohort. In contrast to SOX11 expression in other malignancies, SOX11 expression showed no significant impact on outcome, in our study, when adjusting for prognostic factors and treatment.
Session topic: E-poster
Keyword(s): Burkitt's lymphoma, Transcription factor
Type: Eposter Presentation
Background
The transcription factor SOX11 is normally expressed during embryogenesis in humans. Several studies have shown that SOX11 is aberrantly expressed in various types of haematopoetic and solid malignancies, and appears to affect clinicopathological characteristics. In mantle cell lymphoma, SOX11 serves as a diagnostic antigen and has been shown to be associated with superior outcome (Nordström et al. British Journal of Haematology 2014), although its role as a prognostic indicator remains controversial. In chronic lymphocytic leukemia, SOX11 was associated with inferior overall survival (Roisman et al. Tumor Biol 2015), whereas SOX11 expression correlated with superior outcome in epithelial ovarian cancer (Sernbo et al. BMC Cancer 2011). Various possible target genes and transcriptional programs have been identified, by which SOX11 may exert both repressive, and exaggerative, functions on proliferation (Kuo et al. Oncogene 2015, Vegliante et al. Blood 2013). In Burkitt lymphoma (BL), two small series have reported expression of SOX11 in 30-50 % of cases (Mozos et al. Haematologica 2009, Dictor et al. Haematologica 2009). As of yet, no study has been performed specifically to evaluate the implication of SOX11 expression in BL.
Aims
The aim of this study was to investigate the frequency of SOX11 positive BL cases in a larger joint cohort from Denmark and Sweden, and correlate its expression to clinical and pathological parameters.
Methods
45 BL cases were collected from Sweden and Denmark. Samples were analyzed for expression of SOX11 and other immunohistochemical markers. Clinical data were obtained from the Danish Lymphoma Database (LYFO) and the Swedish Lymphoma Registry. Additionally, 9 pediatric BL cases were analyzed for SOX11 expression, but with no clinical data available.
Results
In the adult study population, 14/45 (31 %) expressed nuclear staining of SOX11. The SOX11 positive subgroup had a higher median age (53 compared to 41), as well as a larger proportion with elevated LDH. Other prognostic factors were equally distributed between the groups. Although a similar proportion of patients received high-intensive chemotherapy in both subgroups, 3 (21 %) received no treatment in the SOX11 positive cohort. There was no significant difference in immunohistochemical characteristics between SOX11 positive and negative cases.Five-year overall survival (OS) in the SOX11 positive group was 57 %, compared to 77 % in the SOX11 negative cohort. When adjusting for treatment and and prognostic factors in multivariable analysis, no significant difference in outcome was seen between groups (hazard ratio: 1.5, 95 % confidence interval: 0.3-6.3, p=0.6). In the pediatric cohort, 5/9 (56 %) expressed SOX11.
Conclusion
SOX11 expression was found in a minority of BL cases, and was associated with higher age in the adult BL cohort. In contrast to SOX11 expression in other malignancies, SOX11 expression showed no significant impact on outcome, in our study, when adjusting for prognostic factors and treatment.
Session topic: E-poster
Keyword(s): Burkitt's lymphoma, Transcription factor
{{ help_message }}
{{filter}}